These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31738937)

  • 1. Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins.
    Erdem Tuncdemir B; Mergen H; Saglar Ozer E
    Eur J Pharmacol; 2019 Dec; 865():172803. PubMed ID: 31738937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH; Sze M; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of AVPR2 mutants found in Turkish patients with nephrogenic diabetes insipidus.
    Erdem B; Schulz A; Saglar E; Deniz F; Schöneberg T; Mergen H
    Endocr Connect; 2018 Jan; 7(1):56-64. PubMed ID: 29117938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus.
    Bockenhauer D; Carpentier E; Rochdi D; van't Hoff W; Breton B; Bernier V; Bouvier M; Bichet DG
    Nephron Physiol; 2010; 114(1):p1-10. PubMed ID: 19816050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
    Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
    J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.
    Bernier V; Lagacé M; Lonergan M; Arthus MF; Bichet DG; Bouvier M
    Mol Endocrinol; 2004 Aug; 18(8):2074-84. PubMed ID: 15166253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors.
    Wüller S; Wiesner B; Löffler A; Furkert J; Krause G; Hermosilla R; Schaefer M; Schülein R; Rosenthal W; Oksche A
    J Biol Chem; 2004 Nov; 279(45):47254-63. PubMed ID: 15319430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
    Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
    Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity.
    Méchaly I; Laurent F; Portet K; Serrano J; Cros G
    Eur J Pharmacol; 1999 Nov; 383(3):287-90. PubMed ID: 10594321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice.
    Krieg SM; Sonanini S; Plesnila N; Trabold R
    J Neurotrauma; 2015 Feb; 32(4):221-7. PubMed ID: 25111427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
    Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
    J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic diabetes insipidus.
    Erdem Tuncdemir B
    J Recept Signal Transduct Res; 2022 Dec; 42(6):573-579. PubMed ID: 35901021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
    Prosperi F; Suzumoto Y; Marzuillo P; Costanzo V; Jelen S; Iervolino A; Guarino S; La Manna A; Miraglia Del Giudice E; Perna AF; Zacchia M; Cordat E; Capasso G; Trepiccione F
    Sci Rep; 2020 Oct; 10(1):16383. PubMed ID: 33009446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor.
    Hawtin SR
    J Biol Chem; 2006 May; 281(21):14604-14. PubMed ID: 16565083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
    Morello JP; Salahpour A; Laperrière A; Bernier V; Arthus MF; Lonergan M; Petäjä-Repo U; Angers S; Morin D; Bichet DG; Bouvier M
    J Clin Invest; 2000 Apr; 105(7):887-95. PubMed ID: 10749568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
    Mouillac B; Mendre C
    Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.
    Janovick JA; Spicer TP; Bannister TD; Scampavia L; Conn PM
    PLoS One; 2017; 12(8):e0181830. PubMed ID: 28767678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic diabetes insipidus.
    Morello JP; Bichet DG
    Annu Rev Physiol; 2001; 63():607-30. PubMed ID: 11181969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin(4-9) fragment activates V1a-type vasopressin receptor in rat supraoptic neurones.
    Gouzènes L; Dayanithi G; Moos FC
    Neuroreport; 1999 Jun; 10(8):1735-9. PubMed ID: 10501566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus.
    Morello JP; Salahpour A; Petäjä-Repo UE; Laperrière A; Lonergan M; Arthus MF; Nabi IR; Bichet DG; Bouvier M
    Biochemistry; 2001 Jun; 40(23):6766-75. PubMed ID: 11389590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.